Top

Published in:

01-10-2018 | Review

Pancreatic cancer stem cells: features and detection methods

Authors: Toshiyuki Ishiwata, Yoko Matsuda, Hisashi Yoshimura, Norihiko Sasaki, Shunji Ishiwata, Naoshi Ishikawa, Kaiyo Takubo, Tomio Arai, Junko Aida

Published in: Pathology & Oncology Research | Issue 4/2018

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high incidence of distant metastasis and recurrence. Cancer stem cells (CSCs), which are pluripotent, self-renewable, and capable of forming tumors, contribute to PDAC initiation and metastasis and are responsible for resistance to chemotherapy and radiation. Three types of experimental methods are commonly used to identify CSCs: CSC-specific marker detection, a sphere-formation assay that reveals cell proliferation under non-adherent conditions, and detection of side-population (SP) cells that possess high intracellular-to-extracellular pump functions. Several CSC-specific markers have been reported in PDACs, including CD133, CD24, CD44, CXCR4, EpCAM, ABCG2, c-Met, ALDH-1, and nestin. There remains controversy regarding which markers are specific to PDAC CSCs and which are expressed alone or in combination in CSCs. Examining characteristics of isolated CSCs and discovering CSC-specific treatment options are important to improve the prognosis of PDAC cases. This review summarizes CSC-detection methods for PDAC, including CSC-marker detection, the sphere-formation assay, and detection of SP cells.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027 PubMedCrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedCrossRef

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 PubMedCrossRef

Ahrendt SA, Pitt HA (2002) Surgical management of pancreatic cancer. Oncology (Williston Park) 16(6):725–734 discussion 734, 736-728, 740, 743

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155 PubMedCrossRef

Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20(10):1218–1249. https://doi.org/10.1101/gad.1415606 PubMedCrossRef

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117. https://doi.org/10.1038/nature09515 PubMedPubMedCentralCrossRef

Lee CJ, Dosch J, Simeone DM (2008) Pancreatic cancer stem cells. J Clin Oncol 26(17):2806–2812. https://doi.org/10.1200/JCO.2008.16.6702 PubMedCrossRef

Hermann PC, Mueller MT, Heeschen C (2009) Pancreatic cancer stem cells--insights and perspectives. Expert Opin Biol Ther 9(10):1271–1278. https://doi.org/10.1517/14712590903246362 PubMedCrossRef

10.

Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, Jauch KW, Bruns CJ (2009) Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbeck's Arch Surg 395(1):1–10. https://doi.org/10.1007/s00423-009-0502-z CrossRef

11.

Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66(19):9339–9344. https://doi.org/10.1158/0008-5472.CAN-06-3126 PubMedCrossRef

12.

Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, Luttges J, Offerhaus GJ (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25(5):579–586PubMedCrossRef

13.

Kure S, Matsuda Y, Hagio M, Ueda J, Naito Z, Ishiwata T (2012) Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int J Oncol 41(4):1314–1324. https://doi.org/10.3892/ijo.2012.1565 PubMedCrossRef

14.

Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11(3):291–302. https://doi.org/10.1016/j.ccr.2007.01.012 PubMedCrossRef

15.

Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF (2007) Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171(1):263–273. https://doi.org/10.2353/ajpath.2007.061176 PubMedPubMedCentralCrossRef

16.

Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Perez-Gallego L, Redston M, Tuveson DA (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66(1):95–106. https://doi.org/10.1158/0008-5472.CAN-05-2168 PubMedCrossRef

17.

Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi H (2007) Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 132(2):720–732. https://doi.org/10.1053/j.gastro.2006.11.027 PubMedCrossRef

18.

Morrison SJ, Spradling AC (2008) Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132(4):598–611. https://doi.org/10.1016/j.cell.2008.01.038 PubMedPubMedCentralCrossRef

19.

Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68(3):918–926. https://doi.org/10.1158/0008-5472.CAN-07-5714 PubMedPubMedCentralCrossRef

20.

De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M (2009) First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. Drug Saf 32(3):239–244PubMedCrossRef

21.

Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Hayashi A, Nakata K, Tanaka M (2010) Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum Pathol 41(10):1466–1474. https://doi.org/10.1016/j.humpath.2010.04.004 PubMedCrossRef

22.

Hong SP, Wen J, Bang S, Park S, Song SY (2009) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125(10):2323–2331. https://doi.org/10.1002/ijc.24573 PubMedCrossRef

23.

Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I, Van Laethem JL (2009) High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 100(9):1444–1451. https://doi.org/10.1038/sj.bjc.6605020 PubMedPubMedCentralCrossRef

24.

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Butzow R, Coukos G, Zhang L (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5(4):e10277. https://doi.org/10.1371/journal.pone.0010277 PubMedPubMedCentralCrossRef

25.

Ishiwata T, Matsuda Y, Naito Z (2011) Nestin in gastrointestinal and other cancers: Effects on cells and tumor angiogenesis. World J Gastroenterol 17(4):409–418. https://doi.org/10.3748/wjg.v17.i4.409 PubMedPubMedCentralCrossRef

26.

Kawamoto M, Ishiwata T, Cho K, Uchida E, Korc M, Naito Z, Tajiri T (2009) Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol 40(2):189–198. https://doi.org/10.1016/j.humpath.2008.02.022 PubMedCrossRef

27.

Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T (2011) Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 11(5):512–523PubMedPubMedCentralCrossRef

28.

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. https://doi.org/10.1016/j.stem.2007.06.002 PubMedCrossRef

29.

Matsuda Y, Yoshimura H, Ueda J, Naito Z, Korc M, Ishiwata T (2014) Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rgamma(null) (NOG) mice. Am J Pathol 184(3):674–685. https://doi.org/10.1016/j.ajpath.2013.11.014 PubMedPubMedCentralCrossRef

30.

Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6(1):92–97PubMed

31.

Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX (2008) Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 14(24):3903–3907PubMedPubMedCentralCrossRef

32.

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037. https://doi.org/10.1158/0008-5472.CAN-06-2030 PubMedCrossRef

33.

Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218–2227 e2215. https://doi.org/10.1053/j.gastro.2011.08.009 PubMedCrossRef

34.

Sarkar FH, Li Y, Wang Z, Kong D (2009) Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 64(5):489–500PubMedPubMedCentral

35.

Matsuda Y, Kure S, Ishiwata T (2012) Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 45(2):59–65. https://doi.org/10.1007/s00795-012-0571-x PubMedCrossRef

36.

Bednar F, Simeone DM (2009) Pancreatic cancer stem cells and relevance to cancer treatments. J Cell Biochem 107(1):40–45. https://doi.org/10.1002/jcb.22093 PubMedCrossRef

37.

Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038 PubMedCrossRef

38.

Shmelkov SV, St Clair R, Lyden D, Rafii S (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37(4):715–719. https://doi.org/10.1016/j.biocel.2004.08.010 PubMedCrossRef

39.

Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1):R10. https://doi.org/10.1186/bcr1855 PubMedPubMedCentralCrossRef

40.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828PubMed

41.

Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351(4):820–824. https://doi.org/10.1016/j.bbrc.2006.10.128 PubMedCrossRef

42.

O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110. https://doi.org/10.1038/nature05372 PubMedCrossRef

43.

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111–115. https://doi.org/10.1038/nature05384 PubMedCrossRef

44.

Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL (2008) Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate 68(9):1007–1024. https://doi.org/10.1002/pros.20765 PubMedCrossRef

45.

Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A (2008) Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8:48. https://doi.org/10.1186/1471-2407-8-48 PubMedPubMedCentralCrossRef

46.

Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S (2008) CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 98(8):1389–1397. https://doi.org/10.1038/sj.bjc.6604307 PubMedPubMedCentralCrossRef

47.

Taieb N, Maresca M, Guo XJ, Garmy N, Fantini J, Yahi N (2009) The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 278(2):164–173. https://doi.org/10.1016/j.canlet.2009.01.013 PubMedCrossRef

48.

Boivin D, Labbe D, Fontaine N, Lamy S, Beaulieu E, Gingras D, Beliveau R (2009) The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48(18):3998–4007. https://doi.org/10.1021/bi900159d PubMedCrossRef

49.

Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF (2011) CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One 6(11):e28053. https://doi.org/10.1371/journal.pone.0028053 PubMedPubMedCentralCrossRef

50.

Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, Yokozaki H, Hori Y (2011) Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1alpha-dependent manner in pancreatic cancer cells. Pathobiology 78(4):181–192. https://doi.org/10.1159/000325538 PubMedCrossRef

51.

McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7(4):489–497. https://doi.org/10.1158/1541-7786.MCR-08-0360 PubMedCrossRef

52.

Lonardo E, Hermann PC, Heeschen C (2010) Pancreatic cancer stem cells - update and future perspectives. Mol Oncol 4(5):431–442. https://doi.org/10.1016/j.molonc.2010.06.002 PubMedPubMedCentralCrossRef

53.

Thomas RM, Kim J, Revelo-Penafiel MP, Angel R, Dawson DW, Lowy AM (2008) The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57(11):1555–1560. https://doi.org/10.1136/gut.2007.143941 PubMedCrossRef

54.

Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, Garcia-Garcia E, Lopez-Rios F, Matsui W, Maitra A, Hidalgo M (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8(2):310–314. https://doi.org/10.1158/1535-7163.MCT-08-0924 PubMedPubMedCentralCrossRef

55.

Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Buchler MW, Zoller M, Salnikov AV, Herr I (2010) Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70(12):5004–5013. https://doi.org/10.1158/0008-5472.CAN-10-0066 PubMedCrossRef

56.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE (2011) ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6(6):e20636. https://doi.org/10.1371/journal.pone.0020636 PubMedPubMedCentralCrossRef

57.

Rao CV, Mohammed A (2015) New insights into pancreatic cancer stem cells. World J Stem Cells 7(3):547–555. https://doi.org/10.4252/wjsc.v7.i3.547 PubMedPubMedCentralCrossRef

58.

Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, Wyche JH, Anant S, Houchen CW (2011) DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71(6):2328–2338. https://doi.org/10.1158/0008-5472.CAN-10-2738 PubMedPubMedCentralCrossRef

59.

Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW (2009) Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 137(2):649–659, 659 e641-642. https://doi.org/10.1053/j.gastro.2009.05.004 PubMedPubMedCentralCrossRef

60.

Jaks V, Barker N, Kasper M, van Es JH, Snippert HJ, Clevers H, Toftgard R (2008) Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet 40(11):1291–1299. https://doi.org/10.1038/ng.239 PubMedCrossRef

61.

Mizuno N, Yatabe Y, Hara K, Hijioka S, Imaoka H, Shimizu Y, Ko SB, Yamao K (2013) Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Front Physiol 4:269. https://doi.org/10.3389/fphys.2013.00269 PubMedPubMedCentralCrossRef

62.

Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C (2011) Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol 46(8):966–973. https://doi.org/10.1007/s00535-011-0422-x PubMedCrossRef

63.

Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, Fang GQ, Li EM (2011) MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol 17(1):79–88. https://doi.org/10.3748/wjg.v17.i1.79 PubMedPubMedCentralCrossRef

64.

Gou S, Liu T, Wang C, Yin T, Li K, Yang M, Zhou J (2007) Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 34(4):429–435. https://doi.org/10.1097/MPA.0b013e318033f9f4 PubMedCrossRef

65.

Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, Magnoni L, Dandrea M, Montagna L, Ritelli R, Scarpa A, Bakker A (2011) Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep 31(1):45–55. https://doi.org/10.1042/BSR20100018 PubMedCrossRef

66.

Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, Wang C (2011) Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci 12(3):1595–1604. https://doi.org/10.3390/ijms12031595 PubMedPubMedCentralCrossRef

67.

Ishiwata T, Hasegawa F, Michishita M, Sasaki N, Ishikawa N, Takubo K, Arai T, Aida J (2018) Electron microscopic analysis of different cell types in human pancreatic cancer spheres. Oncol Lett 15:2485–2490. https://doi.org/10.3892/ol.2017.7554 PubMedCrossRef

68.

Matsuda Y, Ishiwata T, Yoshimura H, Yamashita S, Ushijima T, Arai T (2016) Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis. Pancreas 45(1):93–100. https://doi.org/10.1097/MPA.0000000000000427 PubMedCrossRef

69.

Bhagwandin VJ, Shay JW (2009) Pancreatic cancer stem cells: fact or fiction? Biochim Biophys Acta 1792(4):248–259. https://doi.org/10.1016/j.bbadis.2009.02.007 PubMedPubMedCentralCrossRef

70.

Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101(39):14228–14233. https://doi.org/10.1073/pnas.0400067101 PubMedPubMedCentralCrossRef

71.

Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ, Xu XX (2009) A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56(5):371–378PubMedCrossRef

72.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219. https://doi.org/10.1158/0008-5472.CAN-05-0592 PubMedCrossRef

73.

Burkert J, Otto WR, Wright NA (2008) Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol 214(5):564–573. https://doi.org/10.1002/path.2307 PubMedCrossRef

74.

Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M, Gou SM (2008) Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14(6):925–930PubMedPubMedCentralCrossRef

75.

Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z (2012) Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 180(5):1928–1941. https://doi.org/10.1016/j.ajpath.2012.01.020 PubMedPubMedCentralCrossRef

76.

Telford WG (2013) Stem cell identification by DyeCycle Violet side population analysis. Methods Mol Biol 946:163–179. https://doi.org/10.1007/978-1-62703-128-8_11 PubMedCrossRef

77.

Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427. https://doi.org/10.1146/annurev.bi.62.070193.002125 PubMedCrossRef

78.

Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137(3):1102–1113. https://doi.org/10.1053/j.gastro.2009.05.053 PubMedCrossRef

79.

Eng JW, Mace TA, Sharma R, Twum DYF, Peng P, Gibbs JF, Pitoniak R, Reed CB, Abrams SI, Repasky EA, Hylander BL (2016) Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer 4:33. https://doi.org/10.1186/s40425-016-0136-y PubMedPubMedCentralCrossRef

80.

Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C (2013) Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 8(10):e76518. https://doi.org/10.1371/journal.pone.0076518 PubMedPubMedCentralCrossRef

81.

Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K, Campos-Olivas R, Grana O, Viera CR, Yuneva M, Sainz B Jr, Heeschen C (2015) MYC/PGC-1alpha Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab 22(4):590–605. https://doi.org/10.1016/j.cmet.2015.08.015 PubMedCrossRef

Title: Pancreatic cancer stem cells: features and detection methods
Authors: Toshiyuki Ishiwata
Yoko Matsuda
Hisashi Yoshimura
Norihiko Sasaki
Shunji Ishiwata
Naoshi Ishikawa
Kaiyo Takubo
Tomio Arai
Junko Aida
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0420-x

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment

Correction to: Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment

Oral Health May Affect the Performance of mRNA-Based Saliva Biomarkers for Oral Squamous Cell Cancer

MiR-184 Retarded the Proliferation, Invasiveness and Migration of Glioblastoma Cells by Repressing Stanniocalcin-2

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy